article thumbnail

Genetic screening before prescribing could benefit millions, study finds

pharmaphorum

“Our work shows the benefits that patients and the NHS could get from rolling out a national screening programme as part of their plans to embed pharmacogenomics in clinical practice by 2025, and that this testing could be effectively delivered by community pharmacists. Estimating the potential impact of implementing pre?emptive

article thumbnail

14th Annual RNA Therapeutics Conference

pharmaphorum

billion by 2025, growing at a CAGR of 7.5%. Director, Clinical Pharmacology. Clinical Science Director. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. Chief Medical Officers.

article thumbnail

COVID-19 has propelled the regulatory industry years ahead

pharmaphorum

8 It’s encouraging to see this as one of the goals in the EMA’s 2025 Regulatory Sciences Strategy. Integrated pathways for evaluation and regulatory approval could help reduce delays, in addition to more adaptive regulatory systems that will encourage innovation. Published 2021 Apr 9. Regulatory science strategy. Available from: [link].

Vaccines 143